

## SUPPLEMENTARY MATERIAL

### **Deletion in mice of X-linked, Brugada syndrome- and atrial fibrillation-associated *Kcne5* augments ventricular Kv currents and predisposes to ventricular arrhythmias**

Jens-Peter David<sup>1=</sup>, Ulrike Lisewski<sup>2=</sup>, Shawn M. Crump<sup>3</sup>, Thomas A. Jepps<sup>1</sup>, Elke Bocksteins<sup>4†</sup>, Nicola Wilck<sup>2‡</sup>, Janine Lossie<sup>2‡</sup>, Torsten K. Roepke<sup>2#</sup>, Nicole Schmitt<sup>1#</sup>, Geoffrey W. Abbott<sup>3#\*</sup>

<sup>1</sup>Danish National Research Foundation Centre for Cardiac Arrhythmia and Dept. of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark

<sup>2</sup>Charité - Universitätsmedizin Berlin- Medizinische Klinik und Poliklinik m. S. Kardiologie und Angiologie, CCM and Experimental and Clinical Research Center (ECRC), Lindenberger Weg 80, 13125 Berlin, Germany

<sup>3</sup>Bioelectricity Laboratory, Dept. Physiology and Biophysics, University of California, Irvine, CA, U.S.A.

<sup>4</sup>Laboratory for Molecular Biophysics, Physiology and Pharmacology, Department for Biomedical Sciences, University of Antwerp, Antwerp, Belgium

<sup>=</sup>equally contributing authors; <sup>#</sup>equally contributing authors

<sup>†</sup>present address: Quality by Design NV, 2610 Wilrijk, Belgium


<sup>‡</sup>present address: Omeicos Therapeutics, Robert-Rössle-Straße 10, 13125 Berlin, Germany

<sup>‡</sup>present address: Medizinische Klinik mit Schwerpunkt Nephrologie und Internistische Intensivmedizin Charité – Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany and Experimental and Clinical Research Center (ECRC), Lindenberger Weg 80, 13125 Berlin, Germany

\*CORRESPONDING AUTHOR:

Prof. Geoffrey W. Abbott, Bioelectricity Laboratory, Med Sci D337, Department of Physiology and Biophysics, School of Medicine, University of California, Irvine, CA 92697, U.S.A.

Phone: 1-949-824-3269; E-mail: [abbottg@uci.edu](mailto:abbottg@uci.edu)



**Supplementary Figure S1.** Schematic of a successful homology directed repair HDR of the designed ZFNs and donor vector for *Kcne5*. **A.** Schematic for the donor vector sequence designed to introduce three stop-codons (TGA) for every reading frame (green/purple) as well as an exogenous *TfiI* restriction site (underlined) into the mouse genome *in vivo*. Also shown are endogenous start (ATG) and stop (TAG) codon (bold/black) of *Kcne5*. ZFN binding site (red) and primers for PCR (yellow/blue) and sequencing (yellow/grey). **B.** Detection of introduced *TfiI* site in founder animals. Founder mice were genotyped by *TfiI* digestion of the 320 bp PCR product amplified from ear genomic DNA (1% agarose gel). The PCR product from wildtype mice, lacking the *TfiI* restriction site, could not be digested (lane 1-7), whereas the PCR product from successful ZFN/donor vector treatment could be digested by *TfiI* (lane 8) into two distinct fragments. (Ma – marker, PK – positive control, NK – negative control). **C.** Sequence analysis of the *Kcne5* mutant allele of one founder with correct *TfiI* restriction bands. The target region of the mouse *Kcne5* gene was PCR-amplified from ear genomic DNA (first and second biopsy from 1 and 3 week old animals, respectively). Precise homologous recombination with the donor vector and therefore introduction of three stop codons as well as *TfiI* site insertion was detected by sequencing in this founder animal. Stop codon TGA underlined in red, *TfiI* restriction site underlined in green, endogenous start (ATG) and stop (TAG) codon underlined in black. **D.** Genotyping of *kcne5* mice by PCR. Exemplar agarose gel with *Kcne5*<sup>+/+</sup>, *Kcne5*<sup>+/-</sup> and *Kcne5*<sup>-/-</sup> genotype.

**Supplementary Table S1:** Organ weights of C57BL/6 background *Kcne5<sup>+/+</sup>* and *Kcne5<sup>-/-</sup>* male mice (age of 4 month)

	<i>Kcne5<sup>+/0</sup></i> (n=6)	<i>Kcne5<sup>-/0</sup></i> (n=6)	p (Student`s T test)
HW (mg)	158.0 ± 7.8	145.0 ± 6.4	0.233
LW (mg)	161.8 ± 4.7	149.8 ± 6.3	0.163
HW/BW (mg/g)	4.9 ± 0.1	4.7 ± 0.1	0.240
LW/BW (mg/g)	5.0 ± 0.1	4.9 ± 0.1	0.849
BW (g)	32.2 ± 1.1	30.6 ± 1.4	0.383


HW: heart weight, LW: Lung weight, BW: body weight; Values represent means ± SEM.

**Supplementary Table S2: Echocardiography** parameter of *Kcne5<sup>+/0</sup>* and *Kcne5<sup>-/0</sup>* male mice (ages 3-4 months)

	<i>Kcne5<sup>+/+</sup></i> (n=7)	<i>Kcne5<sup>-/-</sup></i> (n=7)	p (Student`s T test)
Heart rate (beats/min)	440.43 ± 15.56	439.43 ± 18.00	0.821
IVS <sub>d</sub> (mm)	0.76 ± 0.04	0.69 ± 0.05	0.713
LVPW <sub>d</sub> (mm)	0.76 ± 0.05	0.71 ± 0.06	0.829
IVS <sub>s</sub> (mm)	1.14 ± 0.07	1.01 ± 0.07	0.616
LVPW <sub>s</sub> (mm)	1.07 ± 0.07	0.91 ± 0.08	0.526
LV <sub>d</sub> (mm)	4.67 ± 0.10	4.73 ± 0.17	0.469
LV <sub>s</sub> (mm)	3.50 ± 0.12	3.75 ± 0.22	0.365
FS (%)	25.10 ± 1.07	21.19 ± 1.87	0.307
EF (%)	52.50 ± 1.77	44.70 ± 3.63	0.280
Stroke volume (µl)	36.33 ± 3.46	31.67 ± 2.65	0.821
Cardiac output (µl/min)	15.90 ± 1.38	14.03 ± 1.55	0.890
LV mass (mg)	142.45 ± 8.87	130.57 ± 9.20	0.953
HW/BW(mg/g)	4.61 ± 0.23	4.50 ± 0.16	0.984
BW (g)	30.87 ± 0.95	28.90 ± 1.28	0.956


IVS<sub>d</sub> and IVS<sub>s</sub>: intraventricular septum in diastole and systole, LVPW<sub>d</sub> and LVPW<sub>s</sub>: left ventricular posterior wall in diastole and systole, LV<sub>d</sub> and LV<sub>s</sub>: diameter of left ventricle in diastole and systole, FS: fractional shortening, EF: ejection fraction, HW: heart weight, BW: body weight; Values represent means ± SEM.

A






Parameters heart rate, RR interval, PR-interval, QRS interval, R wave amplitude, QT interval, and J wave amplitude are reported as mean±SEM. **A.** ECG analysis of *Kcne5*<sup>-/-</sup> male mice at the age ~5 months compared to age matched male control mice. Heart rate [bpm]: 443.2±11.1 (n=9) vs. 432.0±13.6 (n=10), RR interval [ms]: 136.0±3.2 (n=9) vs. 140.2±4.5 (n=10), PR interval [ms]: 40.6±0.7 (n=8) vs. 40.4±0.8 (n=9), QRS interval [ms]: 8.8±0.3 (n=9) vs. 9.2±0.5 (n=10), R wave amplitude [mV]: 1.51±0.09 (n=9) vs. 1.42±0.07 (n=10), QT interval [ms]: 41.9±0.4 (n=9) vs. 41.5±0.6 (n=9) and J wave amplitude [mV]: 0.10±0.03 (n=9) vs. 0.16±0.04 (n=10). Data were analyzed by unpaired Student's t-test with Welch's correction, no statistically significant changes were observed. **B.** Comparing the ECG analysis between ~8 months old *Kcne5*<sup>-/-</sup> male mice and age matched male control mice. Heart rate [bpm]: 390.6±6.5 (n=20) vs. 403.3±10.1 (n=20), RR interval [ms]: 154.4±2.6 (n=20) vs. 150.4±3.4 (n=20), PR interval [ms]: 42.2±0.9 (n=20) vs. 42.9±1.1 (n=19), QRS interval [ms]: 9.6±0.2 (n=20) vs. 9.3±0.2 (n=20), R wave amplitude [mV]: 1.25±0.04 (n=20) vs. (1.31±0.05 n=20), QT interval [ms]: 44.3±0.6 (n=19) vs. 43.8±0.4 (n=16) and J wave amplitude [mV]: 0.20±0.01 (n=20) vs. 0.23±0.02 (n=20). No statistically significant differences were observed when analyzed with an unpaired Student's t-test with Welch's correction.



**Supplementary Figure S3: *Kcne5* deletion does not alter *Kv*  $\alpha$  subunit transcript expression in mouse hearts.**


- A. Quantification of *Kv2.1* (upper panel) or *Kv4.2* (lower panel) transcript expression in atria and ventricles of male 129/SvEv-C57BL/6 background mice ( $n = 3$ ) by real-time qPCR, normalized to reference genes *ACTB* and *GAPDH*. Data presented as mean  $\pm$  SEM. No statistically significant differences were observed between genotypes.




**Supplementary Figure S3: *Kcne5* deletion does not alter  $K_V \alpha$  subunit transcript expression in mouse hearts.**

**B.** Quantification of  $K_V \alpha$  subunit transcript expression in ventricles of male C57BL/6NCrl background mice ( $n = 3$ ) by real-time qPCR, normalized to GAPDH. Data presented as mean  $\pm$  SEM. No statistically significant differences were observed between genotypes.





**Supplementary Figure S4: Mouse KCNE5 subunits traffic similarly to human KCNE5 subunits.** The mouse clone of KCNE5 (mKCNE5) was found in similar dense clusters and vesicles as the human KCNE5 clone (see figure 6A) when singly expressed in HL-1 cells. Images were acquired using laser confocal microscopy. Merged image is found in the right column. Phalloidin (Pha) was used as a membrane maker.



**Supplementary Figure S5:** Biophysical properties of Kv2.1 co-expressed with wild type or HA-tagged KCNE5. Representative current recordings to determine the activation (left panel) and inactivation (right panel) properties of Kv2.1 + KCNE5 (middle row) and Kv2.1 + HA-KCNE5 (bottom row). The applied pulse protocols are given on top. No significant differences could be detected between wild type and HA-tagged KCNE5.